• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

链激酶和脱氧核糖核酸酶对人体手术创口脓液及脓胸脓液粘度的影响。

Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus.

作者信息

Simpson G, Roomes D, Heron M

机构信息

Department of Thoracic Medicine, Cairns Base Hospital, Queensland.

出版信息

Chest. 2000 Jun;117(6):1728-33. doi: 10.1378/chest.117.6.1728.

DOI:10.1378/chest.117.6.1728
PMID:10858409
Abstract

STUDY OBJECTIVE

To investigate the effects of streptokinase and deoxyribonuclease (DNase) on the viscosity of pus to assess whether the DNase in the old preparation of streptokinase-streptodornase used intrapleurally to treat empyema was contributing to easier drainage of pus compared with purified streptokinase.

DESIGN

In vitro measurement of pus viscosity.

PATIENTS

Pus from three patients with surgically drained soft tissue abscesses and from six patients with empyema thoracis of varying etiology was studied.

INTERVENTIONS

Pus samples were incubated with saline solution as control and with streptokinase, streptokinase-streptodornase, human recombinant DNase, and a mixture of streptokinase and DNase in concentrations approximating those achieved in clinical practice.

RESULTS

Purified streptokinase had little effect on pus viscosity, with a mean reduction of 11.1% in the surgical specimens and 1.7% in the empyema samples. Streptokinase-streptodornase reduced viscosity by a mean of 52.8% in the surgical samples and 94.8% in the empyema samples. Human recombinant DNase reduced viscosity by a mean of 32. 79% in surgical samples and 93.4% in empyema samples. Adding streptokinase to human recombinant DNase produced no further reduction in viscosity. Final viscosities in samples treated with DNase were very similar whatever the starting viscosity.

CONCLUSIONS

DNase significantly reduces pus viscosity, whereas streptokinase has little or no effect, and in empyema may work simply by breaking down loculations. Clinical studies should be undertaken to see if these in vitro changes produce clinical benefits. The simple viscometer devised for these experiments may also prove useful in other contexts.

摘要

研究目的

研究链激酶和脱氧核糖核酸酶(DNase)对脓液黏度的影响,以评估在胸膜腔内使用的链激酶-链道酶旧制剂中的DNase与纯化链激酶相比,是否有助于更轻松地引流脓液。

设计

体外测量脓液黏度。

患者

研究了3例手术引流的软组织脓肿患者和6例病因各异的脓胸患者的脓液。

干预措施

将脓液样本分别与作为对照的盐溶液、链激酶、链激酶-链道酶、重组人DNase以及链激酶和DNase的混合物一起孵育,这些物质的浓度接近临床实际使用的浓度。

结果

纯化链激酶对脓液黏度影响很小,手术标本中平均降低11.1%,脓胸样本中降低1.7%。链激酶-链道酶使手术样本的黏度平均降低52.8%,脓胸样本中降低94.8%。重组人DNase使手术样本的黏度平均降低32.79%,脓胸样本中降低93.4%。向重组人DNase中添加链激酶不会进一步降低黏度。无论起始黏度如何,用DNase处理的样本的最终黏度非常相似。

结论

DNase可显著降低脓液黏度,而链激酶几乎没有影响,在脓胸中可能只是通过破坏分隔起作用。应进行临床研究,以确定这些体外变化是否能带来临床益处。为这些实验设计的简易黏度计在其他情况下可能也很有用。

相似文献

1
Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus.链激酶和脱氧核糖核酸酶对人体手术创口脓液及脓胸脓液粘度的影响。
Chest. 2000 Jun;117(6):1728-33. doi: 10.1378/chest.117.6.1728.
2
Successful treatment of empyema thoracis with human recombinant deoxyribonuclease.用人重组脱氧核糖核酸酶成功治疗胸腔积脓
Thorax. 2003 Apr;58(4):365-6. doi: 10.1136/thorax.58.4.365.
3
Alteplase and DNase for the treatment of pleural empyema in rats.阿替普酶和 DNA 酶治疗大鼠脓胸。
Pulm Pharmacol Ther. 2019 Apr;55:1-4. doi: 10.1016/j.pupt.2019.01.001. Epub 2019 Jan 14.
4
New therapy of pleural empyema by deoxyribonuclease.脱氧核糖核酸酶治疗脓胸新疗法。
Braz J Infect Dis. 2013 Jan-Feb;17(1):90-3. doi: 10.1016/j.bjid.2012.08.019. Epub 2013 Jan 16.
5
A study of empyema thoracis and role of intrapleural streptokinase in its management.脓胸的研究及胸膜腔内链激酶在其治疗中的作用
BMC Infect Dis. 2004 Jun 29;4:19. doi: 10.1186/1471-2334-4-19.
6
Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model.组织型纤溶酶原激活剂联合人重组脱氧核糖核酸酶对兔脓胸模型是有效的治疗方法。
Chest. 2006 Jun;129(6):1577-83. doi: 10.1378/chest.129.6.1577.
7
Efficacy and safety of intrapleural streptokinase in tubercular empyema thoracis - old wine in new wineskin.胸腔内链激酶治疗结核性脓胸的疗效和安全性——陈酒装新瓶。
Trop Doct. 2022 Jan;52(1):23-26. doi: 10.1177/00494755211050193. Epub 2021 Dec 6.
8
Intrapleural heparin or heparin combined with human recombinant DNase is not effective in the treatment of empyema in a rabbit model.在兔模型中,胸膜内注射肝素或肝素与人重组脱氧核糖核酸酶联合使用对脓胸治疗无效。
Respirology. 2006 Nov;11(6):755-60. doi: 10.1111/j.1440-1843.2006.00934.x.
9
The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema.与链激酶或尿激酶相比,玻璃酸酶在体外对溶解局限性脓胸的浓稠脓性渗出物的疗效。
Lung. 2000;178(1):13-8. doi: 10.1007/s004080000002.
10
[Treatment of pleural empyema with streptokinase and streptodornase].[用链激酶和链道酶治疗胸膜积脓]
Pediatr Pol. 1955 Dec;30(12):1145-52.

引用本文的文献

1
Pleural Infection: Diagnosis, Management, and Future Directions.胸膜感染:诊断、管理及未来方向
J Clin Med. 2025 Mar 2;14(5):1685. doi: 10.3390/jcm14051685.
2
Intrapleural Fibrinolysis with Urokinase versus Alteplase in Complicated Pleural Effusions and Empyema: A Prospective Randomized Controlled Trial.尿激酶与阿替普酶用于复杂性胸腔积液和脓胸的胸膜内纤维蛋白溶解治疗:一项前瞻性随机对照试验
Tuberc Respir Dis (Seoul). 2024 Jul;87(3):378-385. doi: 10.4046/trd.2022.0168. Epub 2024 Mar 7.
3
Diagnosis and management of pleural infection.胸膜感染的诊断与管理
Breathe (Sheff). 2023 Dec;19(4):230146. doi: 10.1183/20734735.0146-2023. Epub 2024 Jan 16.
4
Toward Pathogenic Biofilm Suppressors: Synthesis of Amino Derivatives of Pillar[5]arene and Supramolecular Assembly with DNA.迈向致病性生物膜抑制剂:柱[5]芳烃氨基衍生物的合成及与DNA的超分子组装
Pharmaceutics. 2023 Jan 31;15(2):476. doi: 10.3390/pharmaceutics15020476.
5
Can intrapleural alteplase treatment be an alternative to videothoracoscopic deloculation and decortication in pleural empyema?在胸膜脓胸中,胸膜腔内注射纤溶酶治疗能否替代电视胸腔镜下松解术和剥脱术?
Wideochir Inne Tech Maloinwazyjne. 2021 Sep;16(3):580-586. doi: 10.5114/wiitm.2021.103920. Epub 2021 Feb 24.
6
Ambulatory Intrapleural Fibrinolytic Therapy in Highly Viscous Recurrent Malignant Pleural Effusion.高粘性复发性恶性胸腔积液的门诊胸膜内纤维蛋白溶解疗法
Case Rep Oncol. 2021 Mar 16;14(1):466-469. doi: 10.1159/000515077. eCollection 2021 Jan-Apr.
7
Hyaluronic acid in viscous malignant mesothelioma pleural effusion.粘性恶性间皮瘤胸腔积液中的透明质酸
Respirol Case Rep. 2020 Dec 3;9(1):e00694. doi: 10.1002/rcr2.694. eCollection 2021 Jan.
8
Management of Pleural Infection.胸腔感染的管理
Pulm Ther. 2021 Jun;7(1):59-74. doi: 10.1007/s41030-020-00140-7. Epub 2020 Dec 9.
9
Deoxyribonucleases and Their Applications in Biomedicine.脱氧核糖核酸酶及其在生物医学中的应用。
Biomolecules. 2020 Jul 11;10(7):1036. doi: 10.3390/biom10071036.
10
A Primer on the Management of Pleural Effusions.胸腔积液管理入门
Semin Intervent Radiol. 2018 Dec;35(5):486-491. doi: 10.1055/s-0038-1676361. Epub 2019 Feb 5.